Celecoxib safe, effective for brucellosis-associated depression

Celecoxib safe, effective for brucellosis-associated depression

(HealthDay)—Celecoxib seems safe and effective for treatment of depression due to acute brucellosis, according to a study published online May 26 in the Journal of Clinical Pharmacy and Therapeutics.

Sara Jafari, M.D., from the Tehran University of Medical Sciences in Iran, and conducted a involving 40 outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19. Participants were randomized to eight weeks of treatment with celecoxib or placebo as an adjunct to antibiotic therapy.

The researchers observed a significant effect for time × treatment interaction on the HDRS score in repeated-measures analysis (P < 0.001). At the study end there was a significantly greater response to treatment in the celecoxib versus placebo group (50 versus 0 percent; P < 0.001). There were no serious adverse events.

"Celecoxib is a safe and effective treatment for brucellosis-associated depression when compared with placebo," the authors write. "Celecoxib was associated with fast improvement in depressive symptoms, which makes this drug a potentially useful augmentative strategy in patients with brucellosis."


Explore further

People with depression may be more likely to develop Parkinson's disease

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2015 HealthDay. All rights reserved.

Citation: Celecoxib safe, effective for brucellosis-associated depression (2015, May 29) retrieved 21 October 2019 from https://medicalxpress.com/news/2015-05-celecoxib-safe-effective-brucellosis-associated-depression.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
21 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more